What to Expect at the 7th Dermatology Drug Development Summit Europe
With clinical progress evident from Sanofi, AbbVie, Pfizer, Sun Pharma, and BMS’s recent phase 3 entries, this year's 7th Dermatology Drug Development Summit Europe is evolving in line with the industry, doubling down on late-stage data, regulatory pain points and patient access.
Across this summit, delegates will gain practical insight into how leading teams are advancing programmes from late-stage development through to real-world access.
Sessions will unpack how to shorten Europe’s post-approval “500-day gap” from EMA approval to patient access with Sanofi, tackle the uniquely high placebo burden in clinical trials with Inflarx N. V., and explore how advanced imaging and biophysical tools can strengthen differentiation claims with Pierre Fabre Laboratories.
Attendees will also learn how to modernise trial design, endpoints, and site execution from Nektar Therapeutics and Alumis, alongside practical applications of AI-enabled trial design, data handling, and execution shared by Sanofi.
Together, these sessions provide a clear, end-to-end view of how dermatology programmes are being de-risked, differentiated, and accelerated in Europe today.
What’s New for 2026: Unmissable Highlights of the 7th Dermatology Drug Development Summit Europe
Track the clinical inflection point in dermatology by examining how emerging and maturing mechanisms (IL, JAK, TYK2, OX40), alongside antibodies, gene therapies, oligonucleotides and advanced topicals, are moving decisively into Phase II–IV across AD, psoriasis, HS, vitiligo and rare dermatological disorders.
Redesign trials for a late-stage reality by learning how solution providers are adapting protocols to withstand high placebo and vehicle effects, evolving EMA expectations, heterogeneous patient populations, and fragmented European site execution, now critical as more assets advance toward pivotal and confirmatory studies.
Engage in deeper, more candid peer exchange within a single-track, industry-led forum built for a market now defined by late-stage pipelines, outsourcing-driven development models and global scrutiny, prioritising honest benchmarking, practical lessons and collaboration over volume or promotional noise.
Prepare for Europe’s tougher access environment in 2026 through real-world case studies addressing pricing pressure, HTA divergence, post-approval delays, biosimilar competition and payer evidence thresholds, reflecting the growing gap between regulatory approval and patient access.
De-risk pivotal investment earlier by understanding how clinical pharmacology, AI-enabled trial design, advanced imaging and biomarker strategies are being applied before Phase III to strengthen signal confidence, inform go/no-go decisions and support partnering and acquisition readiness.
Explore the Full Events Guide
- 18 World Class Speakers
- 2 deep Dive Pre-Conference Workshops
- 60+ attendees from Pharma & Biotech
- 6+ Hours of Networking Time Available
- 3 Days of Clinical & Commercial Conversations
Attending Companies Include
Explore the Agenda to Discover the Clinical & Access Priorities Shaping Dermatology R&D in 2026
Explore a focused agenda of late-stage case studies, interactive workshops and peer-led discussions tackling clinical design, regulatory access, reimbursement and differentiated dermatology modalities.
Partner to Position Your Solutions at the Centre of Active Dermatology Pipelines
Partner with the summit to showcase your capabilities to senior pharma and biotech teams actively seeking support across biomarkers, imaging, clinical trials, manufacturing and formulation.
Join Biopharma Experts to Connect with the Decision-Makers Driving Dermatology Development Forward
Join 60+ senior leaders from pharma and biotech for high-value networking, candid peer exchange and relationship-building across late-stage development, access and launch in Europe.